Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues

Sanofi’s new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.